臨床研究用バイオチップの欧州市場

Abstract

High Costs Prove a Hurdle to Commercial Adoption

Biochips have emerged as the buzzword in modern day medicine, especially after exhibiting their immense potential in understanding disease pathways at the molecular level. While major scientific breakthroughs in this field offer great value addition to changing the paradigm of diagnostics, many hospitals remain sceptical of investing in these diagnostic kits without knowing their clinical utility. Also, despite the potential to commercialise drugs faster, their premium pricing does not justify the use of biochips in routine research processes. Companies are however striving towards making biochips more affordable and with the combined efforts of research units and regulatory bodies, pricing could be made more feasible for hospitals in medium to long term.

This Frost & Sullivan research service examines the European markets for biochips in clinical research. It analyses the competitive structure and provides strategic recommendations to overcome technical and business challenges confronting the adoption of these applications. The research service also presents valuable end-user feedback that can help companies better tailor their product offerings.

Flexibility of Chip Technology and Multi-parameter Testing Drive Uptake in Clinical Research

In this age of bio revolution, biochips offer the ability to identify and prioritise drug targets through the parallel corroboration of a multitude of gene expressions. The concept of expanding information content by shrinking feature seize is also being probed using technical knowledge borrowed from the semiconductor industry. "With the recent Food and Drug Administration (FDA) guidelines on pharmacogenomics, it is anticipated that there would be steady growth in the biochips market," says the analyst of this research service. "Companies can expect to see a boost in their revenues and market share if they focus on developing disease-specific biomarkers with genomics/proteomics technology."

The biochips market is witnessing a shift in strategies wherein the established array companies are looking to gain better penetration rates by collaborating with firms that own biocontent. Recent alliances in the global markets are expected to have a significant impact on the European market as they bring together companies with key intellectual properties and adequate financial resources. With the trend towards strategic alliances, a balanced combination of collaboration strategies, contracts and pricing is likely to make the DNA market more feasible for use in elaborate laboratory experimentation.

Personalised Medicine Holds Promise for Future Development

Personalised medicine -- a concept that promises to individualise diagnosis -- is expected to slowly make its presence in the commercial diagnostic segment. Although this is a positive driver for the growth of array technologies in clinical diagnostics, the critical hurdle lies in obtaining consistent and statistically relevant readouts. This calls for systems that are easy to use and are equipped with robust infrastructure to provide consistent results in the clinical research phase. Although the novel and radical concept of personalised medicine is expected to alter the nature of diagnostics in the future, its impact on the commercial market is likely to be more profound in the medium to long run.

Companies strongly feel biochip technologies need to address relevant research questions in order to be commercialised in diagnostics. "At present, biochip technologies employed in clinical diagnostics are thought to account for only around 10 per cent of all biochip applications with the remainder being used in drug discovery applications," says the analyst. "Most companies are employing open platforms in their biochips since this helps boost revenues and ensures healthy dividends that compensate the high research and development (R&D) costs involved in enabling these technologies."

Table of Contents

• 1. Executive Summary
  • 1. Executive Summary
    • 1. Executive Summary
• 2. Glossary & Exchange Rates
  • 1. Glossary and Exchange Rates
    • 1. Glossary of Terms
    • 2. Exchange Rates
• 3. Total Biochips Market
  • 1. Market Overview
    • 1. Market Overvie
  • 2. Segmentation
    • 1. Market Model
  • 3. Market Engineering Measurements for Biochips Market- Clinical Research Applications
    • 1. Market Engineering Measurements
  • 4. Biochip Market Drivers
    • 1. Market Drivers
      • a. Miniaturisation and Multi-parameter Tests
      • b. Strategic Alliances
      • c. Turn Around Time
      • d. Personalised Medicine - For a Healthier Tomorrow
      • e. High Throughput Systems & Human Genome Research
      • f. Disease Pathologies Encourage Employment of Protein Arrays
  • 5. Market Restraints/Challenges
    • 1. Market Restraints/Challenges
      • a. Cost: The major Downside to the Growth of these Biochip Techniques for Clinical Diagnostic Applications
      • b. Standardisation of Gene Data Pool
      • c. Reimbursement Climate
      • d. Technology Transfer from Bench to Bedside
      • e. Content Customisation
      • f. Manufacturing Processes Involve High Costs and Time
      • g. Data Comparison Across Platforms
      • h. Unavailability of Capture Agents: A Major Stumble Block
      • i. Drug Targets Seek the Aid of Protein Chips
      • j. Long-term Safety Studies
  • 6. Total European Revenue Forecasts
    • 1. Revenue Forecasts
  • 7. Technological Trends
    • 1. Technology Trends
  • 8. Competitive Landscape
    • 1. Competitive Structure
  • 9. End-user Trends
    • 1. End-user Trends
• 4. DNA Chips
  • 1. Introduction
    • 1. Introduction
  • 2. Market Engineering Measurements
    • 1. Market Engineering Measurements
  • 3. Market Revenue Forecasts
    • 1. Revenue Forecasts
  • 4. Competitive Landscape
    • 1. Competitive Landscape
• 5. Protein Chips
  • 1. Introduction
    • 1. Introduction
  • 2. Market Engineering Measurements
    • 1. Market Engineering Measurements
  • 3. Market Revenue Forecasts
    • 1. Revenue Forecasts
  • 4. Competitive Landscape
    • 1. Competitive Landscape
• 6. Frost & Sullivan Awards
  • 1. Frost & Sullivan Awards for the European Biochips Market -Clinical Research Applications
    • 1. Frost & Sullivan Award Description
  • 2. Product Quality Innovation Award
    • 1. Award Description
  • 3. Technology Innovation Award
    • 1. Award Description
• 7. Strategic Recommendations
  • 1. Strategic Recommendations for Challenges that confront Biochips in Clinical Research
    • 1. Strategies
• 8. DSD for Biochips in Clinical Research Applications
  • 1. Government R&D Expenditure
    • 1. R&D Investment in Biotechnology
  • 2. Pharmaceutical R&D Expenditure
    • 1. Pharmaceutical R&D Expenditure
  • 3. Biotech Companies and Number of Employees
    • 1. Biotech Companies
    • 2. Number of Employees
  • 4. Private Investment in Biotechnology
    • 1. Private Investment in Biotechnology
• 9. Database of Key Industry Participants(DKIP)
  • 1. Key Industry Participants
    • 1. Database of Key Industry Participants